Prof Fabien Reyal is an expert in Oncology at Institut Curie (France). As of October 2026, ScienceLeadR ranks Fabien Reyal in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Fabien Reyal has authored 361 publications, the most recent in 2026, and is an investigator in 7 clinical trials. SLR score: 1,208 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Fabien Reyal Institut Curie France
1 208 ScienceLeadR Reputation 1208
Network Map

Oncology

Subspecialties: Surgery - Pharmacy - Gynecology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2001 - 2026

Source: PubMed

PSL Research University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 361

Citations

Citations: 11 249 1st author: 26 Last author: 60 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments-A VigiBase Disproportionality Analysis Study.
PMID 42522681 — pregnancy, breast neoplasms, docetaxel, neoplasms, ear, drug therapy, pharmacology, breast, therapeutics, pharmacovigilance, fetal growth retardation
Clin Pharmacol Ther20261
[Corrigendum to "Indications for total mastectomy with immediate breast reconstruction in oncology: Surgical strategies tailored to breast morphology and adjuvant treatments" [Ann. Chir. Plast. Esth. 70/6 (2025) p. 539-550]].
PMID 41927437 — surgical oncology, mastectomy, mastectomy, simple, surgery, plastic, mammaplasty, breast, therapeutics
Ann Chir Plast Esthet20260
Improving CTV boost delineation after preoperative systemic therapy in breast cancer using deformable PET/CT registration.
PMID 41926859 — breast neoplasms, neoplasms, positron emission tomography computed tomography, breast, therapeutics
Breast20260
CMV seropositivity associates with poor clinical outcome in triple negative breast cancer.
PMID 41852722 — cells, triple negative breast neoplasms, breast neoplasms, neoplasms, breast, t-lymphocyte subsets, infections
iScience20260
SCANDARE: an institutional dynamic prospective interventional biobanking study.
PMID 41639663 — neoplasms
BMC Cancer20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 4
Phase 3 2
Phase 2 1

By status:

Completed 3
Active not recruiting 2
Recruiting 1
Terminated 1

By type:

Interventional 5
Observational 2

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 3
multicentric5to9 2
multicentricup10 1

Main Topics

Cohort/Consortium Investigators 2

LeadR Networks

Main global connection map